Algernon Pharmaceuticals Inc.

As of February 28, 2026, Algernon Pharmaceuticals Inc. has 5.42M shares outstanding.

These figures are as of February 28, 2026.

As of February 28, 2026, Algernon Pharmaceuticals Inc. maintains a current ratio of 0.25, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended February 28, 2026. Return on assets (ROA) is negative at -47.90, reflecting losses generated across the asset base.

As of the close on May 14, 2026, Algernon Pharmaceuticals Inc.'s stock has declined approximately 52.94% over the past 52 weeks. The 50-day moving average sits at 0.44, while the 200-day moving average is 0.62.

These figures cover the twelve months ended February 28, 2026. Free cash flow yield is negative at -161.55: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -157.98, meaning Algernon Pharmaceuticals Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Algernon Pharmaceuticals Inc.'s most recent stock split took place on April 21, 2026 with a 10:1 split ratio.

As of February 28, 2026, Algernon Pharmaceuticals Inc. has an Altman Z-Score of -79.63, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.